The content on this website is intended solely for veterinarians and other animal health professionals.
By using this website, you confirm that the above applies to you.
Interim report January – September 2021
The period in summary Third quarter July 1 – September 30, 2021 On August 16th the European Commission granted a Marketing Authorisation for Strangvac within the European Union. The Veterinary Medicines Directorate (VMD) of the United Kingdom granted a Marketing...U.S. patent approval for Intervacc’s vaccine against infections caused by Streptococcus suis
Stockholm, November 8, 2021 – Intervacc AB (“Intervacc”) announces that the United States Patent and Trademark Office has granted an approval for Intervacc’s patent application in the United States for a vaccine against Streptococcus suis infections. The...Strangvac, a vaccine against equine strangles, has been granted marketing authorisation in the UK
Stockholm, September 17, 2021 – Intervacc AB (“Intervacc”) announced today that the Veterinary Medicines Directorate (VMD) of the United Kingdom has granted a Marketing Authorisation for Strangvac® within the UK. Strangvac® is a vaccine against equine strangles,...Interim report January – June 2021
The period in summary First half year January 1 – June 30, 2021 On June 17th the Committee for Medicinal Products for Veterinary Use (CVMP) at the European Medicines Agency (EMA) adopted a positive opinion, recommending approval of Strangvac within the EU. On April...Intervacc brings forward the report for the first half of 2021 to August 31, 2021
Stockholm August 25, 2021 – Intervacc has stated in the published financial calendar that the report for the first half of 2021 would be made public on September 3, 2021. The report will be made public on August 31, 2021 in accordance with the rules of the...Nyhetstjänster
